Nuvation Bio Inc. (NUVB)

NYSE: NUVB · IEX Real-Time Price · USD
1.61
0.00 (0.00%)
Mar 28, 2023, 4:00 PM EDT - Market closed
Market Cap 350.66M
Revenue (ttm) n/a
Net Income (ttm) -104.20M
Shares Out 217.80M
EPS (ttm) -0.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 234,149
Open 1.59
Previous Close 1.61
Day's Range 1.59 - 1.66
52-Week Range 1.55 - 6.02
Beta 0.66
Analysts Buy
Price Target 4.04 (+150.93%)
Earnings Date May 8, 2023

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an ad... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 54
Stock Exchange NYSE
Ticker Symbol NUVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for NUVB stock is "Buy." The 12-month stock price forecast is $4.04, which is an increase of 150.93% from the latest price.

Price Target
$4.04
(150.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

The 7 Worst Stocks to Buy Now

Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a f...

Other symbols: ACHRFFIEFRCMULNPRLDWGS
1 week ago - InvestorPlace

Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 week ago - Business Wire

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candid...

3 months ago - Business Wire

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

5 months ago - Business Wire

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

8 months ago - Business Wire

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

8 months ago - Business Wire

Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock?

Nuvation Bio Inc. (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

8 months ago - Zacks Investment Research

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

9 months ago - Business Wire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

NEW YORK , July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised to con...

9 months ago - PRNewsWire

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - July 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvat...

9 months ago - Newsfile Corp

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuva...

9 months ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NUVB #NUVB--The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

9 months ago - Business Wire

FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why

The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December...

9 months ago - Benzinga

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

9 months ago - Business Wire

Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

11 months ago - Business Wire

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidat...

1 year ago - Business Wire

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.

1 year ago - Zacks Investment Research

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET fam...

1 year ago - Benzinga

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therape...

1 year ago - PRNewsWire

Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones

David Hung, M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P.

1 year ago - PRNewsWire

Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme

NEW YORK, Dec. 15, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therape...

1 year ago - PRNewsWire

Why Nuvation Bio Shares Are Rising

Nuvation Bio Inc (NYSE:NUVB) shares are trading higher after the company announced FDA clearance of its investigational new drug application for NUV-422. "FDA clearance of our third IND application fo...

1 year ago - Benzinga

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therape...

1 year ago - PRNewsWire

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeu...

1 year ago - PRNewsWire

Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therape...

1 year ago - PRNewsWire